Kornimate/medical-research-clean huggingface dataset:
regulation of intestinal and hepatic lipoprotein production by glucose and fructose

Conditions: Hyperlipidemia

Summary: increased postprandial plasma triglycerides are associated with increased cardiovascular risk. chronic consumption of carbohydrates is associated with increased levels of triglycerides. very few studies have assessed the effect of acute consumption of carbohydrates on plasma triglycerides and lipoprotein production and clearance. the present study aims to assess the effects of acute administration of glucose and fructose on hepatic and intestinal lipoprotein production.

each subject will be studied twice 4-6 weeks apart in random order in this single blinded study. a nasoduodenal tube will be sited under fluoroscopic guidance the day prior to the study.in study a they will receive intraduodenal intralipid (20% at 60 ml/hour) alongside 60 ml/hour of 20% dextrose or fructose for 15 hours starting at 4am. in study b they will receive 60 ml/hour of intraduodenal intralipid with 60ml/hour of normal saline for 15 hours from 4am. a pancreatic clamp (octreotide with replacement glucose, insulin, glucagon and growth hormone) will be started at 7am. from 9am an iv bolus of deuterated-glycerol (d5-glycerol) along with a regular infusion of deuterated leucine (l-\[5,5,5-2h3\]. regular blood samples will be drawn to assess lipoprotein kinetics.

Eligibility criteria:
inclusion criteria: 1. men and women, aged 18 to 60 years 2. body mass index 20 kg/m2 to 27 kg/m2 3. hemoglobin above 130g/l. 4. normal glucose tolerance in response to a 75g, 2-hr ogtt exclusion criteria: 1. subject has a history of hepatitis/hepatic disease that has been active within the previous two years. 2. any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (cr \> 1.5 mg/dl), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic bp \> 100 or systolic \> 180) or proliferative retinopathy 3. history of diabetes or ogtt indicative of diabetes or impaired glucose tolerance. 4. any history of a mi or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ecg, unstable angina, or decompensated heart failure. 5. any laboratory values: ast \> 2x uln; alt \> 2x uln tsh \> 6 mu/l 6. current addiction to alcohol or substances of abuse as determined by the investigator. 7. mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation 8. taking any prescription or non-prescription medications at the time of the study 9. having donated blood three months prior to and three months post study procedures 10. a pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. those who test positive for pregnancy will be excluded. -

Keywords: intestinal lipoprotein apo b48 and apob100 pancreatic clamp
microbial restoration in inflammatory bowel diseases

Conditions: Fecal Microbiota Transplantation; Crohn Disease; Inflammatory Bowel Diseases; Microbiome

Summary: this is a prospective, two-centre, double-blind, parallel-arm, randomised, placebo-controlled trial evaluating the impact of fmt on patients with active crohn's disease.

the study will be conducted in two parts. the first part will involve all patients undergoing an optimisation phase, followed by randomisation into either intervention or placebo arms of the induction phase of the study. for patients achieving a pre-determined clinical response threshold at week 8 they will be re-randomised into the maintenance phase of the trial for a further 44 weeks. fmt will be anaerobically prepared, freeze-thawed for administration.

Eligibility criteria:
inclusion criteria: active crohn's disease * confirmed endoscopic active inflammation (unless isolated small bowel disease that is inaccessible by endoscopy in which case sonographic inflammation is sufficient) within 6 months of study entry and * cdai score of 220-450 and * one of the following: * crp ≥5mg/l * faecal calprotectin ≥100μg/g * inflammation on imaging (either intestinal ultrasound or magnetic resonance imaging) * willing and able to attend the study sites for regular endoscopic procedures. exclusion criteria: active perianal or fistulising disease; pregnant or intending to become pregnant within 12 months; enteropathy or colitis other than crohn's disease; symptomatic intestinal stricture likely to require surgical treatment; presence of a stoma; presence of an ileoanal pouch; total white cell count less than 3.0 x 109/l; albumin less than 20g/l; immunodeficiency (beyond that caused by immune suppressants used for the treatment of ibd) e.g. hiv or common variable immune deficiency; anaphylaxis/severe allergy to food; thiopurine, methotrexate, biologic agent or small molecule inhibitors or aminosalicylates whose dose has been modified within the past two months, 1 month and two weeks of study entry, respectively; prebiotic, probiotic or antibiotic therapy, or over-the-counter supplements therapy in the two weeks prior to study entry; rectal topical crohn's disease therapy in the 2 weeks prior to study entry; prednisolone dose \>20mg or budesonide dose \>6mg; unwilling or unable to taper corticosteroids to zero within 8 weeks of initial fmt; active gastrointestinal infection; alcohol consumption of a dependent nature; primary sclerosing cholangitis; any condition that the treating gastroenterologist deems to pose a theoretical risk to the patient undertaking fmt; any patient that the treating clinicians feel is incapable of participating in the safe use of fmt.
2 doses of an approved drug being studied for a new indication for the prevention of postoperative nausea and vomiting (0869-091)

Conditions: Postoperative Nausea and Vomiting

Summary: the purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay.

the duration of treatment is 4 weeks.

Eligibility criteria:
inclusion criteria: * patient is at least 18 years of age. * patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery). * patient is scheduled to receive general anesthesia. * patient is scheduled to receive postoperative opioids.
circulating androgen levels are not affected by the administration of vaginal micronized progesterone for withdrawal bleeding in patients with polycystic ovarian syndrome

Conditions: Anovulation; Polycystic Ovary Syndrome; Hyperandrogenism

Summary: hormonal evaluation of women who are suspected of having polycystic ovary syndrome (pcos) involves the measurement of basal levels of androgens and 17-hydroxyprogesterone (17-ohp), which are generally used to establish the presence of hyperandrogenemia. in general, these levels are obtained during the follicular phase to maintain sampling uniformity and avoid spurious increases due to corpus luteum function. however, because most hyperandrogenic patients are oligo/amenorrheic, it is frequently necessary to administer a progestogen to induce withdrawal bleeding and properly time the blood sampling. several medications have been described to properly induce withdrawal bleeding , with medroxyprogesterone acetate (mpa) being the most widely use. however, synthetic compounds as mpa do not replicate precisely the constellation of biologic activities of the parent hormone and results in a temporary, albeit clinically relevant, suppression in ovarian function and circulating androgen levels , in addition of several adverse side effects . in this study, it is hypothesized that the administration of natural progesterone vaginally, which will avoid hepatic first pass, may result in significantly less hormonal suppression. the authors test this hypothesis by prospectively determining the effect of vaginal micronized progesterone (omp), administered for the induction of withdrawal bleeding, on the circulating androgen and 17-ohp levels in women with pcos.


Eligibility criteria:
inclusion criteria: * chronic ovulatory dysfunction, defined as intermenstrual intervals of \>45 days or a total of \<8 menstrual cycles per year * polycystic ovaries, defined as at least one ovary with \>12 follicles between 2 and 9 mm or an ovarian volume \>10 ml * clinical hyperandrogenism, defined by a ferriman gallwey score \>8 exclusion criteria: * non-classic congenital adrenal hyperplasia, * hyperprolactinemia * thyroid dysfunction * oral contraceptives pills taken at least 3 months before the study
investigation of the impact of noninvasive prenatal testing for fetal aneuploidy on utilization of prenatal diagnostic procedures and pregnant women's views

Conditions: High Risk Pregnancy

Summary: this is a prospective, single-institution observational study to be conducted at 4 clinics within the southern california permanente medical group. pregnant women who present for prenatal genetic counseling at the designated clinics and who meet study eligibility criteria will be offered the option of the verifi® prenatal test by a trained, licensed and certified genetic counselor (gc) . women who elect the verifi® prenatal test will have a blood sample drawn by peripheral venipuncture that will be sent to the verinata health cap-accredited clinical laboratory (redwood city, ca). results will be reported to the ordering health care provider by the laboratory within 8-10 business days and will be shared with the subject by their provider. subject care and decision-making following nipt result will be clinically managed by the provider with his/her subject and is not dictated by the study protocol. all eligible women who provide informed consent, whether they elect or decline nipt will be asked to complete a short questionnaire on their views of prenatal testing. the uptake of invasive prenatal procedures (cvs and/or amniocentesis) by the total prospective cohort will be collected through review of electronic medical records (emr). a historical cohort with matched demographic and pre-test indications to the prospective cohort will be identified from the emr for comparison in the primary analysis.


Eligibility criteria:
inclusion criteria * age 18 years or older at enrollment * clinically confirmed singleton pregnancy * gestational age between 10 weeks, 0 days and 20 weeks, 0 days * referred for prenatal genetic counseling due to increased risk for fetal aneuploidy (advanced maternal age (ama ≥ 35 years at delivery, high-risk prenatal screen result, abnormal fetal ultrasound finding consistent with fetal aneuploidy, and/or history of prior affected pregnancy for fetal aneuploidy) * pregnancy records accessible and available for data collection (e.g., results from screening, ultrasound examinations, invasive prenatal procedures if performed, and infant hospital discharge exam) * able to provide consent for participation using language-appropriate forms exclusion criteria * invasive prenatal procedure (amniocentesis or cvs) already performed * history of demised or vanished co-twin (spontaneous or following in vitro fertilization)
adapting cognitive behavioral therapy (cbt) for chinese americans

Conditions: Major Depression

Summary: the goals of this study were to a) test whether cognitive behavioral therapy (cbt) is effective in treating depressed chinese americans, b) to develop and test the effectiveness of culturally adapt cbt, and c) to test the differential outcomes of the two treatments.

it is now known that ethnic minorities are less likely to receive quality health services and evidence worse treatment outcomes when compared with other groups (iom, 1999; usdhhs, 2001). moreover, there continues to be a shortage of systematic investigations examining the efficacy of evidence-based treatments (ebts) with ethnic minorities, especially among chinese americans. developing interventions that are both empirically grounded and that are culturally sensitive and compatible with chinese culture is one promising strategy that may improve treatment outcomes for this understudied group. the goal of this study is to culturally adapt a cognitive-behavioral therapy manual for use with depressed chinese american patients. this study will be among the first to develop a culturally adapted ebt for use with this ethnic group and will involve three study phases. phase i of the study will focus on modifying and refining a cbt intervention protocol into a manualized treatment for chinese americans. phase two involves a randomized controlled trial (rct) comparing the effects of the culturally adapted cbt treatment manual with nonadapted cbt. phase three will involve further refinement of the treatment manual, data analysis, and report writing. patients will be recruited from an ethnic-specific mental health center that specializes in treating asian american clientele to participate in the study. patients will be randomly assigned to either the adapted cbt treatment or the nonadapted cbt treatment. moreover, feedback from patients and therapists in both conditions will be used to further refine the new treatment manual, provide valuable information about salient issues in treating depressed chinese americans, and will provide initial estimates of treatment parameters that will be used in preparing a larger r01 proposal to further test the adapted intervention.

Eligibility criteria:
inclusion criteria: * depression, chinese american exclusion criteria: * bipolar, psychotic disorder, primary substance abuse problem, severe medical conditions that induce depression

Keywords: depression cognitive behavioral therapy culture chinese americans psychotherapy
expressive writing in male infertility

Conditions: Infertility, Male

Summary: the purpose of this study is to determine whether expressive writing can be effective in improving the well-being and sperm quality in patients with male infertility.

expressive writing is a therapeutic intervention designed by the psychologist james w. pennebaker. individuals write on three days for about 20 minutes about particularly stressful experiences in their life. several studies showed that expressive writing can have beneficial effects on the frequency of health care utilization and well-being. particularly in patients with rheumatism, kidney cancer and posttraumatic stress disorder expressive writing showed an positive effect on subjective well-being. furthermore, in several studies expressive writing showed a positive effect on immune parameters. as many studies suggest an important negative effect of stress on well-being and sperm parameters in male infertility, we want to investigate the effect of expressive writing in male infertility.the expressive writing condition is compared to a non emotional writing condition, in which individuals write about mainly non emotional topics such as time management. in this randomized-controlled trial subjects were allocated sequentially by block wise randomization (block size of 4). for randomization a computer generated random list was used. the allocation was concealed in a series of numbered sealed envelopes. the envelope was opened immediately before the first writing session.

Eligibility criteria:
inclusion criteria: * male infertile patients with a pathological spermiogram according to who criteria exclusion criteria: * drugs affecting sperm quality * patients with chromosomal anomalies affecting sperm quality (e.g. klinefelter- syndrome) * severe psychiatric disorder defined as psychotic disorder (schizophrenia, bipolar disorder) or substance-related disorder * patients currently in psychotherapeutic or psychiatric therapy

Keywords: expressive writing male infertility
role of exposure in hyperacusis

Conditions: Hyperacusis

Summary: this study focuses on patients with a primary complaint of hyperacusis. hyperacusis has been defined as 'abnormally reduced tolerance to sound'. it shows a high comorbidity with tinnitus, the perception of sound in the absence of a sound source. for the period of one month, hyperacusis and tinnitus severity and exposure to sounds will be evaluated by use of ecological momentary assessment (ema) in all participants. a novel approach to assessments, ema prompts participants during their daily life to answer short questionnaires, increasing ecological validity and minimizing the risk for recall and memory biases. at a randomized time point during the one-month period, participants will individually receive a single psychoeducation session (1h) delivered by an experienced audiologist. the goal of the study is to investigate if the psychoeducation session leads to an increase in exposure to sound and a decrease in hyperacusis severity.


Eligibility criteria:
inclusion criteria: * primary complaint of hyperacusis exclusion criteria: * primary complaint of misophonia * primary complaint of tinnitus * undergoing another therapy at the moment of the study
ultrasound guided vs unguided intra-articular knee injections

Conditions: Osteoarthritis; Inflammatory Arthritis

Summary: to determine the accuracy of unguided versus ultrasound (us) guided knee joint injections in obese patients with no clinically detectable effusion.

patients with bmi \> 30 and no clinically detectable knee effusions, with clinical symptoms and radiographic evidence of knee osteoarthritis or inflammatory arthritis, who have been referred for an intraarticular knee injection with corticosteroid will be randomized to either receive ultrasound guidance or not receive ultrasound guidance for their injection. one group will use the ultrasound guidance to position the needle. the other group will use landmarks to position the needle. for both groups, once the proceduralist is comfortable with needle placement for the injection, contrast dye will be injected and fluoroscopy used, to determine if the needle placement is correct. if it is determined the needle placement is not correct, fluoroscopy will be used to reposition it. once needle placement is determined to be acceptable, the injection will be given. patient demographics will be collected, along with pain scores preprocedure and two weeks post-procedure. subjects are responsible for all clinical costs associated with the injection. there is no remuneration offered for study participation.

Eligibility criteria:
inclusion criteria * bmi \> 30 * no clinically detectable knee effusion * clinical or radiographic evidence of knee osteoarthritis or inflammatory arthritis * must be referred to the pain clinic for treatment exclusion criteria * history of surgery on the affected knee * evidence of untreated systemic infection or systemic immunocompromise * evidence of cutaneous infections near the study knee injection site * patients on warfarin with an inr \> 3.0 * patients on oral antiplatelet or anticoagulant medications will be excluded if they have documented evidence of renal insufficiency (gfr \< 60) * history of iodinated contrast allergy or significant reaction to corticosteroids or lidocaine
medication education for dosing safety

Conditions: Pain; Fever

Summary: acetaminophen and ibuprofen are two of the most commonly used medication products among children \<12 years old, and these medications are frequently prescribed for patients leaving the emergency department (ed), but previous studies have shown that parents often leave the ed unsure of how to safely dose these medications at home. this study will be a randomized controlled trial of a brief medication safety intervention, and examining parental knowledge and implementation of appropriate weight-based dosing.


Eligibility criteria:
inclusion criteria: * parents of children between ages of 90 days to 11.9 years * being discharged with a plan for use of liquid acetaminophen (any age) or ibuprofen (limited to those \>6 months old). the clinical team will determine planned medication use. * parental fluency in english or spanish * ability to be reached by telephone over the next 7 days * planned discharge home. exclusion criteria: * presence of a complex chronic condition in the child * planned use of a non-standard weight-based medication dose. * families will also be excluded if the adult with the child is not a parent or legal guardian.
a clinical evaluation of wear couples in tha

Conditions: Articular Bearing Surface Wear of Prosthetic Joint; Wear of Articular Bearing Surface of Prosthetic Joint; Prosthesis Survival

Summary: clinical evaluation of 4 different bearings in tha. primary parameter being prosthetic survival data.


Eligibility criteria:
inclusion criteria: * \>18 willing to participate informed consents indication for tha exclusion criteria: * \<18 other diseases in the lower extremities than the actual disorder of the hip
an observational study to assess the effect of cumulative ribavirin dose in participants with chronic hepatitis c

Conditions: Hepatitis C, Chronic

Summary: the purpose of this open-label, non-randomized, single-arm, multicentre observational study is to investigate the influence of the cumulative dose (total administered dose/ planned dose) of ribavirin on the sustained virologic response (svr) in participants who have been receiving combination therapy with pegylated interferon alfa-2a (pegasys) and ribavirin (copegus).


Eligibility criteria:
inclusion criteria: * participants with serologically confirmed chronic hepatitis c * participants using and accepting a double method of contraception exclusion criteria: * participants not approved by the national treatment guideline or the interferon committee for combined pegylated interferon-ribavirin treatment * contraindications in the summary of product characteristics of pegylated interferon alpha-2a and ribavirin * participants previously treated with pegylated interferon and/or ribavirin * hepatitis b and human immunodeficiency virus co-infections
rehabilitation care for hip fracture

Conditions: Hip Fracture

Summary: purpose: hip fracture is a common disease on elderly. they become disabled easily if no adequate rehabilitation was given. the aim of the study is to compare the effectiveness of different types of post acute rehabilitation care for hip fracture.

method: this study will recruit 150 peoples with hip fracture from hospitals in taipei from jan 1, 2014 to dec 31, 2014. the subjects from wards are randomly divided into group a, b and group c. each group includes 50 cases of hip fracture. group c received 14 days hospitalization for comprehensive rehabilitation and 6 times home rehabilitation services within 3 months; group b received 14 days hospitalization for comprehensive rehabilitation and group a was control group.

Eligibility criteria:
inclusion criteria: 1. more than 60 years old, 2. hip fracture s/p within 3 months, 3. potential for rehabilitation. exclusion criteria: 1. active infection, such as pneumonia, uti, osteomyelitis, wound infection 2. other uncontrolled medical condition, such as, dyspnea on exertion, acute renal failure, acute coronary syndrome, acute heart failure, uncontrolled diabetes, active malignancy, dvt, possibility of pulmonary embolism, acute psychosis 3. no caregiver 4. no potential for rehabilitation, such as severe dementia, poor cognition, poor cooperation and motivation, poor family support 5. esrd on hemodialysis

Keywords: hip fracture